Skip to main content
. 2017 Dec 24;7(6):285–300. doi: 10.5500/wjt.v7.i6.285

Table 2.

Case reports in the literatures on de novo proliferative glomerulonephritis with monoclonal IgG deposits in renal allografts

Case Age at diagnosis Gender Onset time (mo) Type of IgG deposits C1q deposition Native kidney disease Pattern of glomerular injury Monoclonal gammopathy Ref.
1 24 M 43 IgG3κ N/A T1DM MPGN None Albawardi et al[64] (2011)
2 68 F 156 IgG1κ N/A PKD MPGN None Albawardi et al[64] (2011)
3 38 F 72 IgG3κ 1+ T1DM MesGN or EC N/A Hussain et al[72] (2017)
4 61 F 98 IgG3κ C1q MPGN EC None Al-Rabadi et al[73] (2015)
5 40 F 132 IgG3κ N/A MPGN MPGN None Al-Rabadi et al[73] (2015)
6 46 M 49 IgG1κ 1+ FSGS MesGN N/A Li et al[77] (2017)
7 69 M 6 IgG3κ 1+ Obesity (FSGS?) MPGN N/A Merhi et al[75] (2017)

EPGN: Endocapillary proliferative glomerulonephritis; FSGS: Focal segmental glomerulosclerosis; MesGN: Mesangioproliferaitve glomerulonephritis; MPGN: Membranoproliferative glomerulonephritis; N/A: Not available; PGNMID: Proliferative glomerulonephritis with monoclonal IgG deposits; PKD: Polycystic kidney disease; T1DM: Type 1 diabetes mellitus; EC: Endocapillary proliferative; M: Male; F: Female.